



09-22-04

DAE
TFW

Docket: 28575/US/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor:	Rajinder Singh	
Appln. No.:	10/631,029	
Filing Date:	July 29, 2003	Examiner: Unknown
Title:	Methods for Treating or Preventing Diseases with 2,4-Pyrimidinediamine Compounds	Group Art Unit: 1632

PETITION UNDER 37 CFR 1.182

Mail Stop **MISSING PARTS**
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Express Mail mailing label number: EV 533898369 US
Date of Deposit: September 21, 2004

I hereby certify that this document or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to Mail Stop **Missing Parts**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Kim Anderson

Name

Signature

Dear Sir:

Pursuant to 37 C.F.R. 1.182 Applicant hereby requests that the above identified nonprovisional patent application be corrected by addition of pages 767-770. Enclosed is a copy of the return receipt postcard received August 19, 2003 from the United States Patent and Trademark Office indicating 785 pages of the specification, claims and abstract were received by the United States Patent and Trademark Office.

Also, it is my practice to review the entire application and count every page before it is mailed to the United States Patent and Trademark Office, on July 29, 2003 I personally counted every page of the application to confirm that all material was included in the application. I have included a copy of pages 767-770 as previously supplied to you as noted above.

Applicant respectfully requests that pages 767-770 be added to your system to make to our application complete for the filing of Application Serial No. 10/631,029 filed July 29, 2003.

09/23/2004 HALI11 00000019 10631029

01 FC:1460

130.00 OP

Enclosed is a check in the amount of \$130.00 for the petition fee (37 CFR 1.17(h)). The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment to Deposit Account 04-1420

Respectfully submitted,
DORSEY & WHITNEY LLP

Customer Number 25763

Date:

September 21, 2004

By:

Scott D. Rothenberger

Scott D. Rothenberger

Reg. No. 41,277


Intellectual Property Department

Suite 1500

50 South Sixth Street

Minneapolis, MN 55402-1498

(612) 340-8819



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/631,029	07/29/2003	Rajinder Singh	28575/US/US

CONFIRMATION NO. 3056

FORMALITIES LETTER



OC000000013694019

Scott D. Rothenberger
 DORSEY & WHITNEY LLP
 Intellectual Property Department
 50 South Sixth Street, Suite 1500
 Minneapolis, MN 55402-1498

Date Mailed: 09/01/2004

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

*Filing Date Granted*Items Required To Avoid Abandonment:

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The statutory basic filing fee is missing.
Applicant must submit \$ 385 to complete the basic filing fee for a small entity.
- The oath or declaration is missing.
A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$65 for a small entity in compliance with 37 CFR 1.27, must be submitted with the missing items identified in this letter.

The following item(s) appear to have been **omitted** from the application:

- Page(s) **767-770** of the specification (description and claims).

I. Should applicant contend that the above-noted omitted item(s) was in fact deposited in the U.S. Patent and Trademark Office (USPTO) with the nonprovisional application papers, a copy of this Notice and a petition (and \$130.00 petition fee (37 CFR 1.17(h))) with evidence of such deposit **must** be filed within **TWO MONTHS** of the date of this Notice. The petition fee will be refunded if it is determined that the item(s) was received by the USPTO.

II. Should applicant desire to supply the omitted item(s) and accept the date that such omitted item(s) was filed in the USPTO as the filing date of the above-identified application, a copy of this Notice, the omitted item(s) (with a supplemental oath or declaration in compliance with 37 CFR 1.63 and 1.64 referring to such items), and a petition under 37 CFR 1.182 (with the \$130.00 petition fee (37 CFR 1.17(h))) requesting the later filing date **must** be filed within **TWO MONTHS** of the date of this Notice.

Applicant is advised that generally the filing fee required for an application is the filing fee in effect on the filing date accorded the application and that payment of the requisite basic filing fee on a date later than the filing date of the application requires payment of a surcharge (37 CFR 1.16(e)). To avoid processing delays and payment of a surcharge, applicant should submit any balance due for the requisite filing fee based on the later filing date being requested when submitting the omitted item(s) and the petition (and petition fee) requesting the later filing date.

III. The failure to file a petition (and petition fee) under the above options (I) or (II) within **TWO MONTHS** of the date of this Notice (37 CFR 1.181(f)) will be treated as a constructive acceptance by the applicant of the application as deposited in the USPTO. **THIS TWO MONTH PERIOD IS NOT EXTENDABLE UNDER 37 CFR 1.136(a) or (b).** In the absence of a timely filed petition in reply to this Notice, the application will maintain a filing date as of the date of deposit of the application papers in the USPTO, and original application papers (*i.e.*, the original disclosure of the invention) will include only those application papers present in the USPTO on the date of deposit.

In the event that applicant elects not to take action pursuant to options (I) or (II) above (thereby constructively electing option (III)), amendment of the specification to renumber the pages consecutively and cancel incomplete sentences caused by any omitted page(s), and/or amendment of the specification to cancel all references to any omitted drawing(s), relabel the drawing figures to be numbered consecutively (if necessary), and correct the references in the specification to the drawing figures to correspond with any relabeled drawing figures, is required. A copy of the drawing figures showing the proposed changes in red ink should accompany with any drawing changes. Such amendment and/or correction to the drawing figures, if necessary, should be by way of preliminary amendment submitted prior to the first Office action to avoid delays in the prosecution of the application.

The applicant needs to satisfy supplemental fees problems indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment:

- Additional claim fees of **\$415** as a small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.


SUMMARY OF FEES DUE:

Total additional fee(s) required for this application is **\$865** for a Small Entity

- **\$385** Statutory basic filing fee.
- **\$65** Late oath or declaration Surcharge.
- Total additional claim fee(s) for this application is **\$415**
 - **\$270** for 30 total claims over 20.
 - **\$145** for multiple dependent claim surcharge.

Replies should be mailed to: Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

*A copy of this notice **MUST** be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



Docket: 28575/US/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor:	Rajinder Singh	Examiner:	Unknown
Application No.:	10/631,029		
Filing Date:	July 29, 2003		
Title:	Methods for Treating or Preventing Autoimmune Diseases with 2,4- Pyrimidinediamine Compounds	Group Art Unit:	1632


TRANSMITTAL LETTER

Mail Stop **MISSING PARTS**
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Express Mail mailing label number: EV 533898369 US
Date of Deposit: September 21, 2004

I hereby certify that this document or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to Mail Stop **Missing Parts**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Kim Anderson


Name
Signature

Dear Sir:


The following documents are enclosed in connection with the above-referenced patent application:

1. Petition (2 pgs.);
2. Exhibit A – Copy of Return Receipt Postcard received August 19, 2003;
3. Exhibit B – Copy of pages 767-770 of the specification (4 pgs.);
4. Part 2 – Copy to Be Returned with Response (3 pgs.);
5. Fee Transmittal (1 pg.);
6. Check in the amount of \$130 to cover Petition fee; and
7. Return Receipt Postcard.

Respectfully submitted,

DORSEY & WHITNEY LLP
Customer Number 25763

Date: September 21, 2004

By: 
Scott D. Rothenberger
Reg. No. 41,277
Intellectual Property Department
Suite 1500
50 South Sixth Street
Minneapolis, MN 55402-1498
(612) 340-8819

APPLICATION FEE TRANSMITTAL SHEET (FY 2004)

Complete if Known

Application No.	10/631,029
Filing Date	July 29, 2003
First Named Inventor	Rajinder Singh
Group Art Unit	1632
Examiner Name	Unknown
Atty. Docket Number	28575/US/Us

METHOD OF PAYMENT (Check One)

1. ☒ The Director is hereby authorized to charge indicated fees and credit any over payments to:
 Deposit Account No.: 04-1420
 Deposit Account Name: DORSEY & WHITNEY LLP
- ☒ Charge any additional fee required under 37 C.F.R. 1.16 and 1.17
☒ Applicant claims small entity status (see 37 C.F.R. 1.27)

2. ☒ Check Enclosed

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee	Small Entity Fee	Fee Description
160	80	<input type="checkbox"/> Provisional Filing Fee
770	385	<input type="checkbox"/> Utility Filing Fee
340	170	<input type="checkbox"/> Design Filing Fee
770	385	<input type="checkbox"/> Reissue Filing Fee

Subtotal (1) N/A

2. EXTRA* CLAIM FEES

Number Claims	Prior	Extra	Fee from Below*	Fee Paid
Total	- 20	=	x	=
Indep.	- 3	=	x	=
Multiple Dependent Claims		=	x	=

Subtotal (2) N/A

***Calculation of Extra Claim Fees**

Large Entity Fee	Small Entity Fee	Fee Description
18	9	Claims in excess of 20
86	43	Independent claims in excess of 3
290	145	Multiple dependent Claim
86	43	Reissue independent claims over original patent
18	9	Reissue claims in excess of 20 and over original patent

FEE CALCULATION (Continued)

3. ADDITIONAL FEES

Large Entity Fee	Small Entity Fee	Fee Description	Fee paid
50	25	Surcharge - late provisional filing fee or cover sheet	
130	65	Surcharge - Late nonprovisional filing fee or oath	
180	180	Submission of IDS	
40	40	Recording each patent assignment per property (times number of properties)	
110	55	Extension for reply within first month	
420	210	Extension for reply within second month	
950	475	Extension for reply within third month	
1,480	740	Extension for reply within fourth month	
2,010	1,005	Extension for reply within fifth month	
770	385	Submission After Final 1.129	
330	165	Notice of Appeal	
330	165	Filing a brief in support of an appeal	
290	145	Request for oral hearing	
110	55	Terminal Disclaimer Fee	
130	130	Petitions to the Commissioner	\$130
50	50	Petitions related to provisional applications	
1,330	665	Utility/Reissue Issue Fee (including advance copies)	
480	240	Design Issue Fee (inc. advance copies)	
770	385	Request for Continued Examination (RCE)	
300	300	Publication fee for early, voluntary, or normal publication	
300	300	Publication fee for re-publication	
110	55	Petition to Revive - unavoidable	
1,330	665	Petition to Revive - unintentional	

OTHER FEE (specify)

Subtotal (3) \$130

Total Amount of Payment: \$130

Submitted by:

CUSTOMER NUMBER

25763

DORSEY & WHITNEY LLP

Intellectual Property Department
 Suite 1500, 50 South Sixth Street
 Minneapolis, MN 55402

Name: Scott D. Rothenberger

Phone No.: (612) 340-8819

Fax No.: (612) 340-8856

Signature:

Scott D. Rothenberger

Reg. No.: 41,277


Date: September 21, 2004

EXHIBIT A



The mail stamp of the United States Patent and Trademark Office on this return receipt postcard acknowledges the filing on the date stamped of the following:

- Utility Patent Application Transmittal
- Application Data Sheet (3 pgs.)
- Specification, Claims, and Abstract (785 pgs.)
- Drawings (19 sheets)
- Return Receipt Postcard

(Small Entity)
16018 U.S. PTO
10/631029

07/29/03

Via Express Mail, Label No.: EV324256247US (with certificate of mailing)

First Named Inventor: Rajinder Singh
Client Name: Rigel Pharmaceuticals
Filing Date: Herewith
Application Title: Methods of Treating or Preventing Autoimmune Diseases....
Attorney/LA Initials: SDR:kks
Mailed: July 29, 2003
Docket No.: 28575/US/US

D
Bp

EXHIBIT B

Table 11																	
Compound	Jurkat		1° T-Cell				1° B-Cell					Monocytes/Macrophage					
	CD69 (in μ M)	IC50 (in μ M)	TNF (in μ M)	IC50 (in μ M)	IL2 (in μ M)	IC50 (in μ M)	GMSCF (in μ M)	IC50 (in μ M)	IL4 (in μ M)	IC50 (in μ M)	IFN γ IC50 (in μ M)	CD69 (in μ M)	IC50 (in μ M)	TNF (in μ M)	IC50 (in μ M)	IL-6 (in μ M)	IC50
R950238	9999																
R950239	9999																
R950240	8.925																
R950241	5.185																
R950244	9999																
R950245	9999																
R950246	9999																
R950247	9999																
R950251	9999																
R950253	10.547																
R950254	2.35																
R950255	9999																
R950261	17.375																
R950262	3.148																
R950263	1.911																
R950264	1.988																
R950265	0.982																
R950266	3.66																
R950267	1.985																

Table 11																	
Compound	Jurkat		I° T-Cell				I° B-Cell				Monocytes/Macrophage						
	CD69 (in μ M)	IC50 (in μ M)	TNF (in μ M)	IC50 (in μ M)	IL2 (in μ M)	IC50 (in μ M)	GMSCF (in μ M)	IC50 (in μ M)	IL4 (in μ M)	IC50 (in μ M)	IFN γ (in μ M)	CD69 (in μ M)	IC50 (in μ M)	TNF (in μ M)	IC50 (in μ M)	IL-6 (in μ M)	IC50 (in μ M)
R950290	9999																
R950291	9999																
R950292	9999																
R950293	9999																
R950294	9.793																
R950295	4.713																
R950296	1.947																
R950344	9999																
R950345	6.09																
R950346	1.948																
R950347	2.704																
R950348	0.224																
R950349	0.363																
R950356	5.731																
R950368	0.125																
R950371	1.105																
R950372	2.192																
R950373	3.614																
R950374	1.65																

Table 11													
Compound	Jurkat		1° T-Cell				1° B-Cell				Monocytes/Macrophage		
	CD69 (in μ M)	IC50 (in μ M)	TNF (in μ M)	IC50 (in μ M)	IL-2 (in μ M)	IC50 (in μ M)	GMSCF (in μ M)	IC50 IL4 (in μ M)	IC50 IFN γ (in μ M)	CD69 (in μ M)	IC50 (in μ M)	TNF (in μ M)	IC50 IL-6 (in μ M)
R950376	18.08												
R950377	5.962												
R950378	9999												
R950379	0.878												
R950380	8.688												
R950381	0.805												
R950382	1.547												
R950383	1.026												
R950385	2.58												
R950386	11.354												

Although the foregoing invention has been described in some detail to facilitate understanding, it will be apparent that certain changes and modifications may be practiced within the scope of the appended claims. Accordingly, the described embodiments are to be considered as illustrative and not restrictive, and the invention is not to be limited to the details given herein, but may be modified within the scope and equivalents of the appended claims.

All literature and patent references cited throughout the application are incorporated by reference into the application for all purposes.